OR
NVCR icon

Olympiad Research’s NovoCure NVCR Stock Holding History

Olympiad Research’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,876
Closed -$221K – 439
2024
Q2 		$221K Buy
+12,876
New +$226K 0.16% 257
2020
Q3 		– Sell
-4,599
Closed -$273K – 420
2020
Q2 		$273K Buy
+4,599
New +$302K 0.19% 140

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Olympiad Research's NVCR Position: Q3 2024 in Review

Olympiad Research sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 12,876 shares — an estimated $221K sold.

Olympiad Research first reported a position in NVCR in Q2 2020 and held it in 2 quarters. The position peaked at $273K in Q2 2020. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Olympiad Research reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Olympiad Research sold 12,876 NovoCure shares in Q3 2024, an estimated $221K.
  • Olympiad Research first reported a position in NovoCure in Q2 2020 and held it in 2 quarters.
  • Olympiad Research's NovoCure position peaked at $273K in Q2 2020.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Olympiad Research's 13F filing for Q3 2024, filed 31 Oct 2024.